Home › Drievoudig negatieve borstkanker › Minnesota › Minneapolis
Drievoudig negatieve borstkanker klinische studies in Minneapolis, MN
8 studies voor Drievoudig negatieve borstkanker zoeken deelnemers op locaties in en rond Minneapolis (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
PRE-ISPY Phase I/II Oncology Platform Program
RekruterenFase 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruterenFase 3
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruterenFase 3
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · 5 mijl verwijderd
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruterenFase 3
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · 5 mijl verwijderd
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruterenFase 1
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruterenFase 2/3
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruterenFase 1
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruterenFase 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · 5 mijl verwijderd
Drievoudig negatieve borstkanker studies in andere steden
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Andere studies in Minneapolis
- Niet-kleincellige longkanker27 studies
- Borstkanker27 studies
- Eierstokkanker24 studies
- Prostaatkanker23 studies
- Kanker (alle vormen)22 studies
- Hartfalen21 studies
- Acute myeloïde leukemie20 studies
- Longkanker20 studies
- Colorectale kanker19 studies
- Endometriumkanker18 studies
- Ziekte van Parkinson17 studies
- Cardiovasculaire ziekte15 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.